Clinical trials: RNA Virus Infections
RNA Virus Infections, Flaviviridae Infections
Vitamin D and Vitamin B12 Supplementation With Pegylated Interferon-Alfa Plus Ribavirin for Treating Chronic Hepatitis C
The purpose of this study is to evaluate the effectiveness of the supplementation of vitamins D and B12 in combination with Pegylated Interferon-Alfa and Ribavirin in the treatment of genotype 1 chronic hepatitis C, who do not…
- Conditions
- RNA Virus Infections, Flaviviridae Infections, Hepatitis C, Hepatitis C, Chronic
- Trial name
- NCT02120274
- Testing
- Vitamin D, Vitamin B 12
- Where
- Brazil
- Volunteers
- 85 people
- Sponsor
- Federal University of São Paulo
Hepatitis C
Rapid Hepatitis C Elimination Trial- A Pilot Study of Daclatasvir/Asunaprevir/BMS-791325 With or Without Ribavirin To Treat Hepatitis C Virus
The purpose of this study is to determine whether treatment with Daclatasvir/Asunaprevir/BMS-791325, with or without ribavirin, for 8, 6, or 4 weeks is feasible for the treatment of genotype 1a chronic hepatitis C in patients…
- Trial name
- RHACE 1 (NCT02098616)
- Testing
- DCV/ASV/BMS-791325, DCV/ASV/BMS-791325 + RBV
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Timothy Morgan, MD
Fever
Clinical Immunization Safety Assessment (CISA) Project: Pilot Study to Assess the Effect of Prophylactic Antipyretics on Immune Responses and Fever After IIV
The study team aims to conduct a double-blind, placebo-controlled, pilot study to assess the effect of prophylactic antipyretics on the immune responses and rates of fever after inactivated influenza vaccine (IIV) in children 12…
- Trial name
- NCT01946594
- Testing
- Acetaminophen
- Where
- United States
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Duke University
HIV Infections, Acquired Immunodeficiency Syndrome
Feasibility of Measuring Immune Resp, Activation in Foreskin/Mucosa in HIV-, Uncircumcised High-HIV-risk MSM, Lima Peru
Rectal and genital sampling in HIV prevention trials permits assessments at the site of HIV entry. Yet the safety and acceptability of circumcision and sigmoidoscopy (and associated abstinence recommendations) are unknown in…
- Conditions
- HIV Infections, Acquired Immunodeficiency Syndrome, Lentivirus Infections, Retroviridae Infections
- Trial name
- HVTN 914 (NCT02630082)
- Testing
- Circumcision, Flexible sigmoidoscopy
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Virus Diseases, RNA Virus Infections
Safety, Tolerability and Immunogenicity of a Plant-made H7 Virus-like Particle (VLP) Influenza Vaccine in Adults.
A phase I trial conducted in a single centre, observer-blind, randomized, dose-ranging, placebo-controlled study to evaluate the safety, tolerability, and immunogenicity of 2 intramuscular injections of plant-based H7 VLP…
- Conditions
- Virus Diseases, RNA Virus Infections, Respiratory Tract Diseases, Respiratory Tract Infections
- Trial name
- NCT02022163
- Testing
- Low dose of H7 VLP vaccine + Alhydrogel, Med dose of H7 VLP vaccine + Alhydrogel, High dose of H7 VLP vaccine + Alhydrogel
- Where
- Canada
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Medicago
Ebola Virus Infection
Safety, Tolerability and Pharmacokinetic First in Human (FIH) Study for Intravenous (IV) TKM-100802
Phase 1, single-center, placebo-controlled, single-blind, first-in-human, single ascending dose (SAD) study followed by a multiple-dose cohort in healthy male and female subjects.
- Trial name
- NCT02041715
- Testing
- TKM-100802 for Injection
- Where
- United States
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- Arbutus Biopharma Corporation
Hepatitis C Virus
Sofosbuvir Plus Ribavirin Administered for Either 12 or 24 Weeks in Treatment-Naive and Treatment-Experienced Egyptian Adults With Chronic Genotype 4 Hepatitis C Virus (HCV) Infection
This study is to to evaluate the safety, tolerability, and efficacy of sofosbuvir (SOF) plus ribavirin (RBV) in Egyptian adults with genotype 4 hepatitis C virus (HCV) infection.
- Trial name
- NCT01838590
- Testing
- SOF, RBV
- Where
- 2 sites in Egypt
- Volunteers
- 103 people
- Sponsor
- Gilead Sciences
Influenza, Human, Orthomyxoviridae Infections
DNA-based Influenza Vaccine in the Elderly
The purpose of this study is to determine whether FVH1, a DNA-based influenza vaccine, will be safe and generally well tolerated in healthy elderly adult volunteers and will result in greater immunogenicity when used to prime the…
- Conditions
- Influenza, Human, Orthomyxoviridae Infections, RNA Virus Infections, Virus Diseases
- Trial name
- NCT01587131
- Testing
- FVH1 - a DNA-based influenza vaccine
- Where
- Canada
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- University of Manitoba
Chronic Hepatitis C
Effect of Teleprevir in Triple Therapy on Intrahepatic Immunological Mechanisms
Chronic hepatitis C infection (HCV) is a disease that affects worldwide about 170 million people. The previous standard of care therapy of chronic HCV patients consists of pegylated-IFN-α combined with ribavirin, and results in…
- Trial name
- ETIM (NCT01641094)
- Where
- 2 sites in Netherlands
- Volunteers
- 20 people
- Sponsor
- Foundation for Liver Research
Hepatitis C
Sofosbuvir (GS-7977) in Combination With PEG and Ribavirin for 12 Weeks in Treatment Experienced Subjects With Chronic HCV Infection Genotype 2 or 3
This study is to evaluate the safety, tolerability, and antiviral efficacy of sofosbuvir (SOF) in combination with peginterferon alfa 2a (PEG) and ribavirin (RBV) administered for 12 weeks in participants with chronic genotype 2…
- Trial name
- NCT01808248
- Testing
- SOF, PEG, RBV
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- Gilead Sciences
Influenza
Validation of the Respirio Flu Test for the Rapid Identification of Influenza A/B
This is a open label, prospective, pair comparison, randomised, multi-centre trial. The primary aim of this study to is to clinically validate the sensitivity and specificity of the Respirio Flu Test (RFT) in detecting Influenza…
- Trial name
- NCT01431768
- Testing
- Respirio Flu Test
- Where
- 2 sites in Australia
- Volunteers
- 250 people
- Sponsor
- Respirio Pty Ltd
HIV Infection
Safety and Effect of The HDAC Inhibitor Panobinostat on HIV-1 Expression in Patients on Suppressive HAART
The purpose of this study is to assess the safety and ability of panobinostat to re-activate HIV transcription in latently infected CD4+ T-cells among HIV-infected patients on stable antiretroviral therapy
- Trial name
- CLEAR (NCT01680094)
- Testing
- Panobinostat
- Where
- Denmark
- Volunteers
- 15 people
- Sponsor
- University of Aarhus
Post-transplant Hepatitis C
Expanded Access Program of Sofosbuvir With Ribavirin and With or Without Pegylated Interferon in Aggressive Post-transplant Hepatitis C
This is a single arm, open-label study which will be opened at specific clinical sites at the request of an investigator for the treatment of individual subjects for whom there are no other treatment options.
- Trial name
- NCT01779518
- Testing
- Sofosbuvir, Ribavirin, Pegylated Interferon
- Sponsor
- Gilead Sciences
HIV Infection, Acquired Immunodeficiency Syndrome
Protease Inhibitor Monotherapy Versus Ongoing Triple-therapy in the Long Term Management of HIV Infection (PIVOT)
The PIVOT trial aims to determine whether a strategy of switching to PI monotherapy is non-inferior to continuing triple-therapy, in terms of the proportion of patients who maintain all the drug treatment options that were…
- Trial name
- PIVOT (NCT01230580)
- Testing
- Protease Inhibitor, Standard-of-care Antiretroviral therapy
- Volunteers
- 587 people
- Sponsor
- Medical Research Council
Virus Diseases, RNA Virus Infections
Immunogenicity, Safety, Tolerability of a Plant-Made H5 VLP Influenza Vaccine
The primary objective is to assess the immunogenicity and safety and tolerability of two consecutive doses of H5 VLP Influenza vaccine given 21 days apart, at three dose levels: in part A: 20 µg, 30 µg and 45 µg combined with…
- Conditions
- Virus Diseases, RNA Virus Infections, Respiratory Tract Diseases, Respiratory Tract Infections
- Trial name
- NCT01244867
- Testing
- 20 micrograms dose H5 VLP, 30 micrograms dose H5 VLP, 45 micrograms dose H5 VLP
- Where
- Canada
- Volunteers
- 255 people, healthy volunteers welcome
- Sponsor
- Medicago
Hepatitis C
Study of Safety, Tolerability, and Anti-Viral Effect of Locteron Compared to PEG-Intron in Patients With Chronic Hepatitis C
The purposes of the PLUS study were to confirm the safety and tolerability of two doses of LocteronTM (320 ug and 640 ug) dosed over four weeks in patients who had failed prior anti-HCV therapies (Panels A and B), and then to…
- Trial name
- PLUS (NCT00593151)
- Testing
- Locteron (controlled-release interferon alpha 2b), pegylated IFNa2b
- Where
- 5 sites in United States
- Volunteers
- 32 people
- Sponsor
- Biolex Therapeutics, Inc.
Infectious Disease by Haemophilus Influenzae Type b
Immunogenicity and Safety Study of 4th LBVH0101 After the Primary Vaccination in LG-VHCL002 Study
This is a multi-center, comparative, two-arm, parallel-group, single-blind, phase III study to assess immunogenicity and safety of 4th LBVH0101 (Haemophilus influenzae type b tetanus toxoid conjugate vaccine) vaccination compared…
- Trial name
- NCT01251133
- Testing
- LBVH0101 (Hib vaccine), Hiberix™ Vaccine
- Where
- South Korea
- Volunteers
- 122 people
- Sponsor
- LG Life Sciences
Virus Diseases, RNA Virus Infections
Safety Study of a Plant-based H5 Virus-Like Particles (VLP) Vaccine in Healthy Adults
The primary objective is to assess the safety and tolerability of two consecutive doses of plant-based H5 VLP, (H5N1) pandemic influenza vaccine combined with Alhydrogel®, given 21 days apart, at three dose levels: 5µg, 10µg and…
- Conditions
- Virus Diseases, RNA Virus Infections, Respiratory Tract Diseases, Respiratory Tract Infections
- Trial name
- NCT00984945
- Testing
- H5 VLP pandemic influenza vaccine 5 µg, H5 VLP pandemic influenza vaccine 10 µg, H5 VLP pandemic influenza vaccine 20 µg
- Where
- Canada
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Medicago
HIV Infections
A Study to Assess the Long-term Efficacy (24 Weeks) of MPC-4326 in Combination With a 2-3 Drug OBR Relative to the Efficacy of a 3-4 Drug ARV Regimen in Treatment Experienced HIV-1 Infected Subjects Who Are Failing Current Antiretroviral Therapy
This phase 2b study is designed to assess the long-term efficacy (24 weeks) of MPC-4326 in combination with a 2-3 drug optimized background regimen (OBR) relative to the efficacy of a 3-4 antiretroviral (ARV) regimen in treatment…
- Trial name
- NCT01026727
- Testing
- MPC-4326 plus a 2-3 drug optimized background regimen (OBR), 3-4 commercially available antiretroviral drugs
- Where
- 25 sites in United States, Canada
- Volunteers
- 2 people
- Sponsor
- Myrexis Inc.